Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on Moderna (MRNA - Research Report) today and set a price target of $506.00. The company's shares opened today at $135.52.R. Cann covers the Healthcare sector, focusing on stocks such as Moderna, Kymera Therapeutics, and CTI BioPharma. According to TipRanks, R. Cann has an average return of -4.3% and a 37.24% success rate on recommended stocks. In addition to Brookline Capital Markets, Moderna also received a Buy from Goldman Sachs's Salveen Richter in a report issued on October 13. However, on October 12, SVB Securities reiterated a Sell rating on Moderna (NASDAQ: MRNA).
https://www.tipranks.com/news/blurbs/brookline-capital-markets-sticks-to-its-buy-rating-for-moderna-mrna?utm_source=advfn.com&utm_medium=referral
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more Moderna Charts.